Form 4: Neumora Therapeutics Reprices Executive Stock Options, Lowering Exercise Price to $0.72

Neumora Therapeutics, Inc. has repriced stock options for Chief Operating and Development Officer Daljit Singh Aurora, reducing the exercise price from $1.69 to $0.72 per share, following stockholder approval on May 28, 2025.

Summary

• Daljit Singh Aurora, Chief Operating and Development Officer of Neumora Therapeutics, Inc. (NMRA), had a total of 1,819,497 stock options repriced.
• The exercise price for these options was significantly reduced from $1.69 per share to $0.72 per share.
• This repricing action was formally approved by the Issuer's stockholders on May 28, 2025.
• The effectiveness of the repricing is contingent on Mr. Aurora remaining in service to Neumora Therapeutics through August 13, 2026.
• The repriced options include both directly held shares and shares held indirectly through the Aurora Family Trust, where members of Mr. Aurora's immediate family are the sole beneficiaries.
• Vesting schedules for the options vary, with some tranches already fully vested and exercisable, while others follow a four-year vesting schedule (25% on the first anniversary, then 1/48th monthly).

Sentiment

Score: 4

Explanation: The repricing is positive for executive incentives and retention, but it inherently signals past stock underperformance, which is negative for existing shareholders. Stockholder approval adds a layer of governance, but the underlying reason for repricing (underwater options) points to challenges.

Positives

• The repricing significantly lowers the exercise price for Daljit Singh Aurora's stock options from $1.69 to $0.72, making them more 'in-the-money' and potentially increasing their intrinsic value to the holder.
• The repricing was approved by stockholders, indicating a level of transparency and alignment between management and shareholders regarding this compensation adjustment.
• The condition of continued service through August 13, 2026, provides an incentive for the executive's long-term commitment and retention within the company.

Negatives

• Stock option repricing typically occurs when a company's stock price has declined significantly, suggesting past underperformance or challenges that have rendered original options 'underwater'.
• While beneficial for the option holder, repricing can be viewed negatively by existing shareholders as it effectively grants new options at a lower price, potentially increasing future dilution if the stock recovers.
• The necessity for repricing might signal a lack of confidence in the stock's ability to reach previous highs in the near term, or a strategic move to re-motivate executives whose original equity incentives have lost value.

Risks

• Stock Price Underperformance: The repricing itself is a strong indicator that the company's stock price has fallen below the original exercise price, highlighting a risk of continued or future underperformance.
• Executive Retention Risk: The explicit condition for the repricing (remaining in service) underscores the company's concern about retaining key executives, especially when their existing equity incentives are no longer motivating.
• Shareholder Dilution: Although not immediate, the future exercise of these repriced options could lead to dilution for existing shareholders, impacting earnings per share and ownership percentages.

Future Outlook

The repricing of stock options is contingent on Daljit Singh Aurora remaining in service to Neumora Therapeutics through August 13, 2026, indicating the company's strategic intent to retain key management for its future operations and development.

Management Comments

• Daljit Singh Aurora holds the title of Chief Operating and Development Officer.
• The Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share, with the repricing subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Industry Context

Stock option repricing is a common practice in the biotechnology and pharmaceutical industries, particularly for early-stage or growth companies whose stock prices can be highly volatile due to clinical trial results, regulatory approvals, or market sentiment. It is often employed to re-incentivize executives when original stock options are 'underwater' (i.e., the current market price is below the exercise price), ensuring the retention and motivation of key talent. This action suggests Neumora Therapeutics may have experienced a significant decline in its stock price, necessitating this adjustment to maintain executive engagement.

Comparison to Industry Standards

• Stock option repricing is a recognized, albeit sometimes debated, practice in industries characterized by high stock price volatility, such as biotechnology.
• The reduction in exercise price from $1.69 to $0.72 represents a substantial decrease (approximately 57%), which is significant but not unprecedented in cases of considerable stock price declines within the biotech sector.
• The inclusion of a continued service condition (through August 13, 2026) is a standard industry practice to ensure executive retention and align incentives with long-term company performance, similar to compensation strategies observed in other biotech firms.
• The approval of the repricing by stockholders is a positive corporate governance aspect, ensuring transparency and shareholder consent, which aligns with best practices for executive compensation adjustments.

Corporate Governance

Related Party Transactions

• Shares held indirectly by Daljit Singh Aurora through the Aurora Family Trust, where members of his immediate family are the sole beneficiaries, are included in the repriced options, indicating a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if repriced options are exercised. The repricing itself suggests past stock underperformance, which is a negative for existing shareholders. However, it could also be viewed as a necessary step to retain critical talent.
• Employees (Executives): Daljit Singh Aurora, as well as other employees and service providers whose options were repriced, directly benefit from the lower exercise price, significantly increasing the potential value of their equity compensation and re-incentivizing their continued service.

Next Steps

• Daljit Singh Aurora must remain in service to Neumora Therapeutics through August 13, 2026, for the repricing to be fully effective.
• The company will continue to operate under the new executive compensation structure for the repriced options.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, Stock Options, Option Repricing, SEC Form 4, Executive Compensation, Daljit Singh Aurora, Beneficial Ownership, Equity Compensation, Biotechnology, Pharmaceuticals